Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy Zhang

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Cancer Discovery|March 6, 2026
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic MutantsCarlos Stahlhut, Anna E Maciag, Kyle A Sullivan, et al.
Science (New York, N.Y.)|June 12, 2025
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interactionDhirendra K Simanshu, Rui Xu, James P Stice, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Cancer Cell|March 11, 2025
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safetyCynthia L Palmer, Britton Boras, Bernadette Pascual, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Cancer Discovery|March 6, 2026
Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic MutantsCarlos Stahlhut, Anna E Maciag, Kyle A Sullivan, et al.
Science (New York, N.Y.)|June 12, 2025
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interactionDhirendra K Simanshu, Rui Xu, James P Stice, et al.
Cancer Cell|September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitorKevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Cancer Cell|March 11, 2025
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safetyCynthia L Palmer, Britton Boras, Bernadette Pascual, et al.
Pageof 5